Dan M Roden MDAssistant Vice Chancellor for Personalized Medicine Professor of Medicine William Stokes Chair in Experimental Therapeutics Professor of Pharmacology
Dan Roden was born and raised in Montreal, and received his medical degree and training in Internal Medicine from McGill University. He then went to Vanderbilt where he trained in Clinical Pharmacology and Cardiology, and has been a faculty member there since. His initial career focus – that he has maintained – was studies of the clinical, genetic, cellular, and molecular basis of arrhythmia susceptibility and variability responses to arrhythmia therapies. Over the last 10 years, Dr. Roden has led Vanderbilt’s broader efforts in pharmacogenomics discovery and implementation. He directs the Vanderbilt DNA databank BioVU, and is one of the key leaders overseeing the Vanderbilt PREDICT project that is preemptively embedding pharmacogenomic variant data in the Vanderbilt electronic medical record.
Dr. Roden served as Director of the Vanderbilt Arrhythmia Service, director of the Division of Clinical Pharmacology (1992-2004), and in 2006 was named Assistant Vice-Chancellor for Personalized Medicine. Dr. Roden has received the Leon Goldberg Young Investigator Award and the Rawls Palmer Progress in Science Award from the American Society for Clinical Pharmacology and Therapeutics and the Distinguished Scientist Award and the Douglas Zipes lectureship from the Heart Rhythm Society. He currently serves on the Science Board of the FDA. He has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians, and fellowship in the American Association for the Advancement of Science.
Recent Contributions to PracticeUpdate:
- Genetic Variant Risk Score Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk
- The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk
- Consistency of Heart–Rate Corrected QT Interval Prolongation and Risk of Sudden Cardiac Death
- Genotype-Guided Warfarin Therapy Not Looking Hopeful
- Genotype-Guided vs Clinical Dosing of Warfarin and Analogues
- Mortality and Cardiovascular Events Associated With Azithromycin Use in Elderly With Pneumonia
- Clinical Decision Support System to Reduce Risk of QT Interval Prolongation
- Rare Potassium Channel Variants Associated With Drug-Induced Long QT Syndrome
- Edoxaban Versus Warfarin in Patients With Atrial Fibrillation
- A Randomized Trial of Genotype-Guided Dosing of Warfarin